文献速递心脑血管急症重症综合管理与镇静镇痛

双联抗血小板治疗对比阿替普酶治疗轻型非致残性急性缺血性卒中:ARAMIS随机临床试验

Dual Antiplatelet Therapy vs Alteplase for Patients With Minor Nondisabling Acute Ischemic Stroke: The ARAMIS Randomized Clinical Trial.
PubMed 文献 · JAMA · 2023-01-01
一句话结论轻型非致残性急性缺血性卒中发病4.5小时内,双联抗血小板治疗在90天极佳功能结局上不劣于静脉阿替普酶。

ARAMIS多中心、开放标签、盲法终点、非劣效性随机临床试验纳入中国38家医院760例轻型非致残性急性缺血性卒中患者(NIHSS≤5分,且多个关键单项评分≤1分),发病4.5小时内随机接受双联抗血小板治疗(氯吡格雷首日300mg后75mg/d共12±2天,阿司匹林首日100mg后100mg/d共12±2天,之后按指南抗血小板至90天)或静脉阿替普酶(0.9mg/kg,最大90mg)后24小时开始指南抗血小板治疗。90天极佳功能结局(mRS 0-1分)双联组93.8%(346/369)vs 阿替普酶组91.4%(320/350),风险差2.3%(95%CI -1.5%至6.2%),单侧97.5%CI下限-1.5%大于-4.5%非劣效界值(非劣效P<.001)。90天症状性颅内出血双联组1/371(0.3%)vs 阿替普酶组3/351(0.9%)。

要点

  • 纳入标准:急性轻型非致残性缺血性卒中,NIHSS≤5分且多个关键单项评分≤1分,发病4.5小时内随机。
  • 双联抗血小板方案:氯吡格雷首日300mg后75mg/d共12±2天,阿司匹林首日100mg后100mg/d共12±2天,之后指南抗血小板至90天。
  • 阿替普酶方案:0.9mg/kg静脉给药(最大90mg),24小时后开始指南抗血小板治疗。
  • 90天极佳功能结局(mRS 0-1分):双联组93.8%(346/369)vs 阿替普酶组91.4%(320/350),风险差2.3%(95%CI -1.5%至6.2%),非劣效P<.001。
  • 90天症状性颅内出血:双联组0.3%(1/371)vs 阿替普酶组0.9%(3/351)。

适用人群与场景

  • 急性轻型非致残性缺血性卒中患者,NIHSS评分≤5分且多个关键单项评分≤1分,发病4.5小时内随机。
  • 中国38家医院,2018年10月至2022年4月纳入,最终随访2022年7月18日。

诊断标准与关键阈值

  • 轻型非致残性卒中定义:NIHSS评分≤5分(量表范围0-42分),且多个关键单项评分≤1分。
  • 非劣效界值:风险差的单侧97.5%CI下限≥-4.5%。

处置流程与药物剂量

  • 双联抗血小板组:氯吡格雷首日300mg,之后75mg每日一次,共12(±2)天;阿司匹林首日100mg,之后100mg每日一次,共12(±2)天;之后按指南抗血小板治疗至90天。
  • 阿替普酶组:静脉阿替普酶0.9mg/kg(最大剂量90mg),给药24小时后开始按指南抗血小板治疗。

研究设计与关键结果

  • 多中心、开放标签、盲法终点、非劣效性随机临床试验,纳入760例患者(双联组n=393,阿替普酶组n=367),719例(94.6%)完成试验。
  • 中位年龄64岁(IQR 57-71),女性223例(31.0%),中位NIHSS评分2分(IQR 1-3)。
  • 90天极佳功能结局(mRS 0-1分):双联组93.8%(346/369)vs 阿替普酶组91.4%(320/350),风险差2.3%(95%CI -1.5%至6.2%),粗相对危险度1.38(95%CI 0.81-2.32)。
  • 非劣效性检验:单侧97.5%CI下限-1.5%,大于-4.5%非劣效界值(非劣效P<.001)。
  • 90天症状性颅内出血:双联组0.3%(1/371)vs 阿替普酶组0.9%(3/351)。

证据类型、等级与局限

  • 证据类型:多中心、开放标签、盲法终点、非劣效性随机临床试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于发病4.5小时内的轻型非致残性急性缺血性卒中患者,双联抗血小板治疗在90天极佳功能结局上不劣于静脉阿替普酶。
  • 双联抗血小板方案为氯吡格雷首日300mg后75mg/d共12±2天,阿司匹林首日100mg后100mg/d共12±2天,之后按指南抗血小板治疗至90天。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Intravenous thrombolysis is increasingly used in patients with minor stroke, but its benefit in patients with minor nondisabling stroke is unknown.

OBJECTIVE: To investigate whether dual antiplatelet therapy (DAPT) is noninferior to intravenous thrombolysis among patients with minor nondisabling acute ischemic stroke.

DESIGN, SETTING, AND PARTICIPANTS: This multicenter, open-label, blinded end point, noninferiority randomized clinical trial included 760 patients with acute minor nondisabling stroke (National Institutes of Health Stroke Scale [NIHSS] score ≤5, with ≤1 point on the NIHSS in several key single-item scores; scale range, 0-42). The trial was conducted at 38 hospitals in China from October 2018 through April 2022. The final follow-up was on July 18, 2022.

INTERVENTIONS: Eligible patients were randomized within 4.5 hours of symptom onset to the DAPT group (n = 393), who received 300 mg of clopidogrel on the first day followed by 75 mg daily for 12 (±2) days, 100 mg of aspirin on the first day followed by 100 mg daily for 12 (±2) days, and guideline-based antiplatelet treatment until 90 days, or the alteplase group (n = 367), who received intravenous alteplase (0.9 mg/kg; maximum dose, 90 mg) followed by guideline-based antiplatelet treatment beginning 24 hours after receipt of alteplase.

MAIN OUTCOMES AND MEASURES: The primary end point was excellent functional outcome, defined as a modified Rankin Scale score of 0 or 1 (range, 0-6), at 90 days. The noninferiority of DAPT to alteplase was defined on the basis of a lower boundary of the 1-sided 97.5% CI of the risk difference greater than or equal to -4.5% (noninferiority margin) based on a full analysis set, which included all randomized participants with at least 1 efficacy evaluation, regardless of treatment group. The 90-day end points were assessed in a blinded manner. A safety end point was symptomatic intracerebral hemorrhage up to 90 days.

RESULTS: Among 760 eligible randomized patients (median [IQR] age, 64 [57-71] years; 223 [31.0%] women; median [IQR] NIHSS score, 2 [1-3]), 719 (94.6%) completed the trial. At 90 days, 93.8% of patients (346/369) in the DAPT group and 91.4% (320/350) in the alteplase group had an excellent functional outcome (risk difference, 2.3% [95% CI, -1.5% to 6.2%]; crude relative risk, 1.38 [95% CI, 0.81-2.32]). The unadjusted lower limit of the 1-sided 97.5% CI was -1.5%, which is larger than the -4.5% noninferiority margin (P for noninferiority <.001). Symptomatic intracerebral hemorrhage at 90 days occurred in 1 of 371 participants (0.3%) in the DAPT group and 3 of 351 (0.9%) in the alteplase group.

CONCLUSIONS AND RELEVANCE: Among patients with minor nondisabling acute ischemic stroke presenting within 4.5 hours of symptom onset, DAPT was noninferior to intravenous alteplase with regard to excellent functional outcome at 90 days.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03661411.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Chen HS, Cui Y, Zhou ZH, et al. Dual Antiplatelet Therapy vs Alteplase for Patients With Minor Nondisabling Acute Ischemic Stroke: The ARAMIS Randomized Clinical Trial. JAMA. 2023. PMID: 37367978. doi:10.1001/jama.2023.7827

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。